DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

UCL St-Luc, Brussels

UZ Leuven, Leuven

Hopital de Jolimont, Haine-Saint-Paul

Institut Catalan de Oncologia Hospital Duran i Reynals, Barcelona

Memorial Sloan Kettering Cancer Center, New York

Northwell Health Cancer Institute, Lake Success

Lehigh Valley Health Network, Allentown

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Asst Grande Ospedale Metropolitano Niguarda, Milan

Hospital la Paz, Madrid

Hospital Universitario HM Sanchinarro, Madrid

Miami Cancer Institute, Baptist Health South Florida, Miami

Oncology Institute Veneto IOVIRCCS, Padua

Azienda Ospedaliero Universitaria di Modena Policlinico, Modena

Biomedical Research Institute Hospital de Valencia, Valencia

University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM, Chicago

Alvin J. Siteman Cancer Center Washington University, St Louis

Kansas University Cancer Center, Kansas City

The University of Texas MD Anderson Cancer Center, Houston

USC Norris Comprehensive Cancer Center Hospital, Los Angeles

UCLA Health, Santa Monica

City of Hope Medical Center, Duarte

Pacific Cancer Care, Monterey

University of Washington/Seattle Cancer Care Alliance, Seattle

Hartford Hospital, Hartford

MidState Medical Center, Meriden

The Hospital of Central Connecticut, New Britain

Smilow Cancer Hospital at Yale-New Haven, New Haven

Massachusetts General Hospital (MGH), Boston

Beth Israel Deaconess Medical Center (BIDMC), Boston

Dana-Farber Cancer Institute, Boston

Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona

Hospital Clinic de Barcelona, Barcelona

Cambridge University Hospitals NHS Foundation Trust, Cambridge

The Royal Marsden Hospital, London

Christie Hospital, Manchester

The Royal Marsden Hospital, Sutton